A randomised, open-label, two-way crossover, single- and multiple-dose relative bioavailability study of tofacitinib extended-release (XR) and tofacitinib immediate-release (IR)

Trial Profile

A randomised, open-label, two-way crossover, single- and multiple-dose relative bioavailability study of tofacitinib extended-release (XR) and tofacitinib immediate-release (IR)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Atopic dermatitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Mar 2016 New trial record
    • 11 Mar 2016 Results from this and other phase I study, published in the Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top